The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'- implications for pre-clinical research and drug testing

Nephrology Dialysis Transplantation

Volumn 33, Issue 8, 2018, Pages 1292-1304

  Gómez, Lidia Anguiano ^a,b   Lei, Yutian ^a   Devarapu, Satish Kumar ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL DEL MAR   (Spain)

Author keywords

Dialysis; Fibrosis; Hyperfiltration; Hypertension; Streptozotocin

Indexed keywords

ALISKIREN; AMLODIPINE; AVOSENTAN; BARDOXOLONE METHYL; CANAGLIFLOZIN; CANDESARTAN; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; EMPAGLIFLOZIN; ENALAPRIL; GLIMEPIRIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; RAMIPRIL; SULODEXIDE; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; VALSARTAN;

ARTICLE; CHRONIC KIDNEY FAILURE; COMBINATION DRUG THERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE EXACERBATION; DRUG EFFICACY; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; KIDNEY HYPERTROPHY; MONOTHERAPY; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENAL PROTECTION; ANIMAL; COMPLICATION; DISEASE MODEL; PANDEMIC; PRECLINICAL STUDY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY FAILURE, CHRONIC; PANDEMICS;

EID: 85035195459     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfx219     Document Type: Article

References (107)

1. Gadegbeku CA et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 2013; 83: 749-756
2. Saito R, Rocanin-Arjo A, You YH et al. Systems biology analysis reveals role ofMDM2 in diabetic nephropathy. JCI Insight 2016; 1: e87877
3. Bohm M et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13: 891-899
4. Mann JF et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553
5. Barnett AH et al. Angiotensin-receptor blockade versus convertingenzyme inhibition in type 2 diabetes and nephropathy. N Engl JMed 2004; 351: 1952-1961
6. Ye M et al. Glomerular localization and expression of angiotensinconverting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J AmSocNephrol 2006; 17: 3067-3075
7. Yao L et al. Effect of telmisartan on expression of protein kinase C-A in kidneys of diabeticmice 1. Acta Pharmacol Sin 2007; 28: 829-838
8. Lei B et al. Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. J Pharmacol Sci 2012; 119: 131-138
9. NAVIGATOR Study Group et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362: 1477-1490
10. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678
11. Zhou G, Cheung AK, Liu X et al. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Clin Sci 2014; 126: 707-720
12. Nangaku M. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy ratmodel. J AmSoc Nephrol 2003; 14: 1212-1222
13. Imai E et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia 2011; 54: 2978-2986
14. Gu J et al. Olmesartan prevents microalbuminuria in db/db diabetic mice through inhibition of angiotensin II/p38/SIRT1-induced podocyte apoptosis. Kidney Blood Press Res 2016; 41: 848-864
15. Haller H et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
16. Yotsumoto T, Naitoh T, Shikada K-I et al. Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice. Jpn J Pharmacol 1997; 75: 59-64
17. Fried LF et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. NEngl JMed 2013; 369: 1892-1903
18. Sasaki M et al. Losartan ameliorates progression of glomerular structural changes in diabetic KKAymice. Life Sci 2004; 75: 869-880
19. Parving H-H et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy.NEngl JMed 2008; 358: 2433-2446
20. Gagliardini E et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol Renal Physiol 2009; 297: F1448-1456
21. Brenner BM et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
22. Hofni A, El-Moselhy MA, Taye A et al. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats. Eur J Pharmacol 2014; 744: 173-182
23. Mogensen CE et al. Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444
24. Chen X-W et al. Irbesartan ameliorates diabetic nephropathy by suppressing the RANKL-RANK-NF-jB pathway in type 2 diabetic db/db mice. Mediators Inflamm 2016; 2016: 1405924
25. Lewis EJ et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
26. Parving HH et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
27. Feldman DL et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136
28. Parving H-H et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes.N Engl JMed 2012; 367: 2204-2213
29. Kelly DJ, Zhang Y, Moe G et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404
30. Dong Y-F et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010; 28: 1554-1565
31. Rossini M et al. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Nephrol Dial Transplant 2010; 25: 1803-1810
32. Packham DK et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J AmSocNephrol 2012; 23: 123-130
33. Gambaro G et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615-1625
34. Yung S, Chau MKM, Zhang Q et al. Sulodexide decreases albuminuria and regulates matrix protein accumulation in C57BL/6 mice with streptozotocininduced type 1 diabetic nephropathy. PLoS One 2013; 8: e54501
35. Watson AMD et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockoutmice. Diabetologia 2010; 53: 192-203
36. Mann JFE et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535
37. Zoja C et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013; 304: F808-819
38. Zeeuw D et al.; BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 2636: 2492-2503
39. Pergola PE et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011; 365: 327-336
40. Chin M et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of type 2 diabetes and obesity. Am J Physiol Renal Physiol 2013; 304: F1438-1446
41. Wang Q et al. Cooperative interaction of CTGF and TGF-b in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4: 4
42. Adler SG et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010; 5: 1420-1428
43. Gray SP et al. Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno-and atheroprotection even in established micro-and macrovascular disease. Diabetologia 2017; 60: 927-937
44. ClinicalTrials.gov. Safety and efficacy of oral GKT137831 in patient with type 2 diabetes and albuminuria. https://clinicaltrials.gov/ct2/show/ NCT02010242?termandfrac14;NCT02010242andrankandfrac14;1 (6 March 2017, date last accessed)
45. Chen S et al. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003; 300: 16-22
46. ClinicalTrials.gov. A study in participants with diabetic kidney disease. https://clinicaltrials.gov/ct2/show/NCT01113801?termandfrac14;NCT01113801&rankandfrac14;1 (6March 2017, date last accessed)
47. Benigni A et al. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 2003; 14: 1816-1824
48. Liang Y et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 2012; 7: e30555
49. Cefalu WT et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950
50. Lin B et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabeticmice. Cardiovasc Diabetol 2014; 13: 148
51. Wanner C et al. Empagliflozin and progression of kidney disease in type 2 diabetes.N Engl JMed 2016; 375: 323-334
52. Brosius FC et al.Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2503-2512
53. Kimmelstiel P,Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 1936; 12: 83-98
54. Magee GM et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52: 691-697
55. Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation.NEngl J Med 1998; 339: 69-75
56. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
57. Navaneethan SD et al. Diabetes control and the risks of ESRD and mortality in patients with CKD. Am J Kidney Dis 2017;: S0272-6386
58. Ritz E, Rychlik I, Locatelli F et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
59. Koye DN et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med 2017; doi: 10.1111/dme.13324
60. Vijayakumar P, Hoyer A, Nelson RG et al. Estimation of chronic kidney disease incidence from prevalence and mortality data in American Indians with type 2 diabetes. PLoS One 2017; 12: e0171027
61. Vigneau C et al. Ten-years trends in renal replacement therapy for endstage renal disease in mainland France: lessons from the French Renal Epidemiology and Information Network (REIN) registry. Nephrologie Therapeutique 2017;: S1769-7255
62. Espinel E et al. Renal biopsy in type 2 diabetic patients. J ClinMed 2015; 4: 998-1009
63. Dabelea D et al. Association of type 1 diabetes vs type 2 diabetes diagnosed during childhood and adolescence with complications during teenage years and young adulthood. JAMA 2017; 317: 825-835
64. Denic A et al. The substantial loss of nephrons in healthy human kidneys with aging. J Am Soc Nephrol 2016; 28: 1-8
65. Hodgin JB et al. Glomerular aging and focal global glomerulosclerosis: a podometric perspective. J AmSocNephrol 2015; 26: 3162-3178
66. Helal I, Fick-Brosnahan GM, Reed-Gitomer B et al. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012; 8: 293-300
67. Klessens CQF et al. An autopsy study suggests that diabetic nephropathy is underdiagnosed. Kidney Int 2016; 90: 149-156
68. Camara NOS, Iseki K, Kramer H et al. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol 2017; 13: 181-190
69. Tonneijck L et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. J Am Soc Nephrol 2017; 28: 1023-1039
70. Anders HJ, Davis JM, Thurau K et al. Clinical implications of basic research nephron protection in diabetic kidney disease. N Engl J Med 2016; 2096-2098
71. Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetesmellitus. Annu RevMed 2015; 66: 255-270
72. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 2012; 74: 351-375
73. Gragnoli G et al. Prevalence of glomerular hyperfiltration and nephromegaly in normo-and microalbuminuric type 2 diabetic patients. Nephron 1993; 65: 206-211
74. Wanke R, Wolf E, Brem G et al. Role of podocyte damage in the pathogenesis of glomerulosclerosis and tubulointerstitial lesions: findings in the growth hormone transgenic mouse model of progressive nephropathy. Verh Dtsch Ges Pathol 2001; 85: 250-256
75. Wiggins JE et al. Podocyte hypertrophy, 'adaptation', and 'decompensation' associated with glomerular enlargement and glomerulosclerosis in the aging rat: prevention by calorie restriction. J AmSoc Nephrol 2005; 16: 2953-2966
76. Sasson AN, Cherney DZ. Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes 2012; 3: 1-6
77. Moriya T et al. Glomerular hyperfiltration and increased glomerular filtration surface are associated with renal function decline in normo-and microalbuminuric type 2 diabetes. Kidney Int 2012; 81: 486-493
78. Kanwar YS, Sun L, Xie P et al. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011; 6: 395-423
79. Hemmingsen B et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; 11: CD008143
80. Fullerton B et al. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014; 2: CD009122
81. Marathe PH et al. American Diabetes Association Standards of Medical Care in Diabetes. J Diabetes 2017; 9: 320-324
82. Thibodeau J-F et al. A novelmousemodel of advanced diabetic kidney disease. PLoS One 2014; 9: e113459
83. RieraMet al. Effect of insulin on ACE2 activity and kidney function in the non-obese diabetic mouse. PLoS One 2014; 9: e84683
84. Vallon V et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. AJP Ren Physiol 2014; 306: F194-F204
85. Martinez-Garcia C et al. Accelerated renal disease is associated with the development of metabolic syndrome in a glucolipotoxic mouse model. Dis ModelMech 2012; 5: 636-648
86. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003; 284: F1138-F1144
87. Ito T et al. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology 2006; 11: 29-35
88. Mallipattu SK et al. Diabetic nephropathy in a nonobese mouse model of type 2 diabetes mellitus. Am J Physiol Renal Physiol 2014; 306: F1008-F1017
89. Kim D-H et al. Beneficial effects of sarpogrelate and rosuvastatin in high fat diet/streptozotocin-induced nephropathy in mice. PLoS One 2016; 11: e0153965
90. Hudkins KL et al. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J AmSocNephrol 2010; 21: 1533-1542
91. Zhao HJ et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006; 17: 2664-2669
92. Kamijo-Ikemori A, Sugaya T, Sekizuka A et al. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenicmice. Nephrol Dial Transpl 2009; 24: 788-800
93. Leelahavanichkul A et al. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model. Kidney Int 2010; 78: 1136-1153
94. Darisipudi MN et al. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 2011; 179: 116-124
95. O'Brien SP et al. Glomerulopathy in the KK.Cg-A(y)/J mouse reflects the pathology of diabetic nephropathy. J Diabetes Res 2013; 2013: 1-13
96. Chan GCW, Tang SCW. Diabetic nephropathy: landmark clinical trials and tribulations.Nephrol Dial Transplant 2016; 31: 359-368
97. Ninichuk V, Kulkarni O, Clauss S et al. Tubular atrophy, interstitial fibrosis, and inflammation in type 2 diabetic db/db mice. An accelerated model of advanced diabetic nephropathy. Eur JMed Res 2007; 12: 351-355
98. Ninichuk V et al. Late onset of Ccl2 blockade with the Spiegelmer mNOXE36-30PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008; 172: 628-637
99. Ninichuk V et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007; 170: 1267-1276
100. Gaikwad AB, Sayyed SG, Lichtnekert J et al. Renal failure increases cardiac histone h3 acetylation, dimethylation, and phosphorylation and the induction of cardiomyopathy-related genes in type 2 diabetes. Am J Pathol 2010; 176: 1079-1083
101. Sayyed SG et al. Podocytes produce homeostatic chemokine stromal cellderived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 2009; 52: 2445-2454
102. Sayyed SG et al. An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 2011; 80: 68-78
103. Sayyed SG et al. Progressive glomerulosclerosis in type 2 diabetes is associated with renal histone H3K9 and H3K23 acetylation, H3K4 dimethylation and phosphorylation at serine 10. Nephrol Dial Transplant 2010; 25: 1811-1817
104. Kumar VRS et al. Cathepsin S cleavage of protease-activated receptor-2 on endothelial cells promotes microvascular diabetes complications. J AmSoc Nephrol 2016; 27: 1635-1649
105. Gava AL, Freitas FP, Balarini CMet al. Effects of 5/6 nephrectomy on renal function and blood pressure in mice. Int J Physiol Pathophysiol Pharmacol 2012; 4: 167-173
106. Menne J et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOXE36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant 2016; 32: 307-315
107. Zeeuw D et al. The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial. Lancet Diabetes Endocrinol 2015; 3: 687-696